ArticleExperimental and therapeutic medicine2025
Metabolomics analysis of gut metabolites in patients with colorectal polyps and in healthy individuals.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to characterize the metabolomic signatures associated with colorectal polyps (CPs) in the gut. A metabolomics analysis was conducted on fecal samples collected from patients diagnosed with CPs as well as from healthy participants. A total of 60 participants were selected for analysis, including 30 patients diagnosed with CPs (CP group) and 30 healthy individuals serving as controls [healthy control (HC) group]. Fecal metabolomes were analyzed using ultra-high performance liquid chromatography and mass spectrometry. Metabolomics analyses revealed a higher abundance of phosphatidylcholine (PC; 16:0/18:2) in the CP group compared with that in the HC group. By contrast, 6-keto-decanoylcarnitine, trimethadione, aalsolinol-1-carboxylic acid, histidyl-proline, norethindrone, gibberellin A12 aldehyde, 6-isopentenyladenine-9-β-D-glucopyranoside, prostaglandin E2, yucalexin B5 and 5,6-dihydroxyprostaglandin F1a were less abundant in the CP group. Moreover, the CP group showed significant Kyoto Encyclopedia of Genes and Genomes pathway alterations compared with the HC group, involving 'neuroactive ligand-receptor interaction', 'aminoacyl-tRNA biosynthesis', 'central carbon metabolism in cancer', and 'phenylalanine, tyrosine and tryptophan biosynthesis'. Notably, PC (16:0/18:2) and prostaglandin A1 could predict CPs, with an area under the curve of 1. The current study showed that fecal metabolites can be used for non-invasive diagnosis of CPs. Moreover, the findings of the present study suggested significant involvement of the aminoacyl-tRNA and aromatic amino acid metabolomic pathways in the development of CPs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.